Stochastic Modeling of B Lymphocyte Terminal Differentiation and Its Suppression by Dioxin
© Zhang et al; licensee BioMed Central Ltd. 2010
Received: 15 October 2009
Accepted: 1 April 2010
Published: 1 April 2010
Upon antigen encounter, naïve B lymphocytes differentiate into antibody-secreting plasma cells. This humoral immune response is suppressed by the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and other dioxin-like compounds, which belong to the family of aryl hydrocarbon receptor (AhR) agonists.
To achieve a better understanding of the immunotoxicity of AhR agonists and their associated health risks, we have used computer simulations to study the behavior of the gene regulatory network underlying B cell terminal differentiation. The core of this network consists of two coupled double-negative feedback loops involving transcriptional repressors Bcl-6, Blimp-1, and Pax5. Bifurcation analysis indicates that the feedback network can constitute a bistable system with two mutually exclusive transcriptional profiles corresponding to naïve B cells and plasma cells. Although individual B cells switch to the plasma cell state in an all-or-none fashion when stimulated by the polyclonal activator lipopolysaccharide (LPS), stochastic fluctuations in gene expression make the switching event probabilistic, leading to heterogeneous differentiation response among individual B cells. Moreover, stochastic gene expression renders the dose-response behavior of a population of B cells substantially graded, a result that is consistent with experimental observations. The steepness of the dose response curve for the number of plasma cells formed vs. LPS dose, as evaluated by the apparent Hill coefficient, is found to be inversely correlated to the noise level in Blimp-1 gene expression. Simulations illustrate how, through AhR-mediated repression of the AP-1 protein, TCDD reduces the probability of LPS-stimulated B cell differentiation. Interestingly, stochastic simulations predict that TCDD may destabilize the plasma cell state, possibly leading to a reversal to the B cell phenotype.
Our results suggest that stochasticity in gene expression, which renders a graded response at the cell population level, may have been exploited by the immune system to launch humoral immune response of a magnitude appropriately tuned to the antigen dose. In addition to suppressing the initiation of the humoral immune response, dioxin-like compounds may also disrupt the maintenance of the acquired immunity.
In response to antigen stimulation, naïve B cells residing in lymphoid organs such as the spleen and lymph nodes differentiate terminally into antibody-secreting plasma cells [1, 2]. This adaptive humoral immune response can be adversely affected by exposure to some environmental chemicals [3–5]. The environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and other dioxin-like compounds with similar structures suppress humoral immunity, mainly by interfering with B cell differentiation and subsequent antibody secretion [5–8]. These compounds, capable of producing a variety of additional toxic responses including cancer, liver damage, and developmental defects, pose a serious potential risk to human health .
Consistent with the idea of two mutually exclusive steady states for a bistable system, naïve B cells are characterized by a transcriptional profile of low Blimp-1 and high Bcl-6/Pax5 expression, whereas plasma cells feature the opposite profile: high Blimp-1 and low Bcl-6/Pax5 [1, 27]. Pax5, acting as a transcriptional repressor, is essential for maintaining the B cell identity . It actively suppresses transcription of the immunoglobulin molecular components including the heavy chain (IgH), κ light chain (Igκ), and J chain, as well as X box protein-1 (XBP-1) which promotes the formation of the cellular apparatus for immunoglobulin assembly and secretion . The transcriptional repression of these genes by Pax5 ensures that naïve B cells neither produce nor secrete antibodies. Upon antigen encounter, the transcriptional profile in naïve B cells is reversed. High expression of Blimp-1, the 'master regulator' of B cell terminal differentiation, activates a number of downstream genes responsible for the plasma cell phenotype . Most importantly, a simultaneous decrease in Pax5 gene expression releases IgH, Igκ, and J chain from repression, leading to enhanced production and secretion of immunoglobulin by plasma cells [28, 29]. Depending on the type of antigen or B cell stimulus and whether T cells are involved, distinct signal transduction pathways may be activated to drive B cells to differentiate into plasma cells [30–33]. In the case of the bacterial endotoxin lipopolysaccharide (LPS), a polyclonal B cell activator, the differentiation is driven, at least in part, via AP-1, a dimeric transcription factor that upregulates Blimp-1 gene transcription [18, 34].
The suppressive effect of TCDD and dioxin-like compounds on the humoral immune response is currently believed to occur via the following mode of action. By binding and activating the aryl hydrocarbon receptor (AhR), TCDD inhibits AP-1 gene transcription indirectly, leading to reduced AP-1 binding to the Blimp-1 promoter [35, 36]. Since AP-1 mediates the action of LPS, TCDD would thus impair the capability of LPS to drive the switching of the transcriptional gene circuit that underlies B-to-plasma cell differentiation, thereby suppressing the formation of antibody-secreting plasma cells . In addition, TCDD-activated AhR binds to the dioxin response element in the 3' α enhancer of the IgH gene, in a limited fashion inhibiting transcription of this immunoglobulin component .
Gene expression is inherently stochastic . This is particularly true for low-abundance proteins, such as transcription factors, for which the steady-state expression level may fluctuate significantly [39–44]. In many circumstances, this intrinsic noise in protein expression is undesirable for cellular homeostasis and as such needs to be minimized. On the other hand there are instances where noise in protein expression is exploited by cells to generate advantageous non-genetic variability in cellular phenotype [12, 45–47]. When an antigen or polyclonal B cell activator is encountered, the all-or-none differentiation of individual B cells occurs in a seemingly random fashion with new plasma cells appearing at various times [22, 32, 34]. This heterogeneity in the differentiation response is likely to be a key factor contributing to the dose response pattern for a population of B cells. It is possible that the intrinsically stochastic gene expression of Blimp-1, Bcl-6, and Pax5 is responsible for the observed heterogeneity in the differentiation response among otherwise identical B cells. In our previous work, we have suggested the emergence of bistability with a deterministic representation of the transcriptional network underlying B cell differentiation . In the current paper, we use a stochastic computational model of this transcriptional network (Figure 1), constrained by experimental data, to examine how stochastic fluctuations in the abundance of the key transcriptional repressors can make B cell differentiation a dose-dependent probabilistic event. The present study indicates that the stochastic effect plays a central role in modulating the shape, especially the steepness, of the dose response curves for both LPS and TCDD, a result with significant implications for quantitative risk assessment of dioxin immunotoxicity.
Virus-free, female B6C3F1 mice (6 weeks of age) were purchased from Charles River (Portage, MI). Mice were randomized, transferred to plastic cages containing bedding (five per cage), and quarantined for 1 week. Mice were given food (Purina certified laboratory chow) and water ad libitum and were not used until their body weight was 17-20 g. Mice were used in accordance with the guidelines set forth by the Michigan State University Institutional Animal Care and Use Committee (East Lansing, MI).
B cell isolation, activation, and TCDD addition
Spleens were isolated and made into single-cell suspensions aseptically. Primary B cells were isolated from the splenocytes by depleting all other cell types by magnetic separation using the B cell isolation kit from Miltenyi Biotec Inc. (Auburn, CA). B cell purity was always greater than 95% as assessed by flow cytometry. B cells were activated with different concentrations of LPS (Sigma-Aldrich Co., St. Louis, MO) at 3 × 106 cells/ml in RPMI 1640 supplemented with 10% BCS, 100 U/ml penicillin, 100 μg/ml streptomycin, and 50 μM 2-ME. Vehicle (0.02% DMSO) and appropriate TCDD concentrations (AccuStandard, New Haven, CT) were added just prior to LPS addition in a 48-well tissue culture plate.
ELISpot assay was performed as previously described with a few modifications . ELISpot filter plates (MultiScreen-HA) (Millipore, Billerica, MA) were precoated with goat anti-mouse IgM antibody (Sigma-Aldrich Co., St. Louis, MO) at 5 μg/ml in a sodium bicarbonate buffer (pH 9.6), washed and blocked with PBS containing 5% BSA. Purified B cells were washed twice and diluted in RPMI containing 10% BCS and loaded into the culture plate wells. Typically 1-4 × 103 cells in 100 μl cell culture media were incubated on precoated plates overnight at 37°C with 5% CO2. After incubation, plates were washed and biotin-conjugated goat anti-mouse IgM antibody (Sigma-Aldrich Co., St. Louis, MO) was added to the plates at 1 μg/ml and incubated for 2 h at room temperature. To develop spots, streptavidin-HRP was added (Sigma-Aldrich Co., St. Louis, MO) followed by the aminoethylcarbazole per staining kit instructions (Sigma-Aldrich Co., St. Louis, MO). Data was acquired and analyzed using the CTL ImmunoSpot system (Cellular Technology Ltd., Shaker Heights, OH).
Measurement of IgM Secretion
IgM secretion was measured using an enzyme-linked immunesorbent assay protocol as previously described . Briefly, supernatants were collected from experimental cultures from which LPS-induced IgM antibody responses were evaluated. Anti-mouse IgM capture antibody (Sigma-Aldrich Co., St. Louis, MO) was added to wells of a 96-well microtiter plate (100 μl/well at 5 μg/ml) and incubated at 4°C overnight. The plate was washed three times with 0.05% Tween-20 in PBS and three times with dH2O. Blocking buffer (3% BSA in PBS) was added to each well and incubated at room temperature for at least 1.5 h. This was followed by the same washing steps described above. Standards (mouse IgM) or supernatant samples were then added to the blocked plate and then incubated at 37°C for 1.5 h. After the incubation, the plate was washed again, followed by addition of 100 μl HRP-conjugated goat anti-mouse IgM detection antibody. After 1.5 h at 37°C, the plate was again washed and 100 μl ABTS (1 mg/ml; Roche, Indianapolis, IN) was added. The detection of the HRP substrate reaction was conducted over a 1 h period using a Synergy HT automated Microplate reader with a 405-nm filter (Bio-Tek, Winooski, VT). The KC4 computer analysis program (Bio-Tek, Winooski, VT) calculated the concentration of IgM in each well based on a standard curve generated from the absorbance readings of known IgM concentrations.
The model structure is illustrated in Additional File 1: Figure S1. Simulation of gene expression control of the transcriptional repressors Bcl-6, Blimp-1, and Pax5 was based on the current understanding of eukaryotic gene regulation [43, 44, 50, 51]. At any given time, a gene could be in one of two discrete transcriptional states: inactive or active, corresponding to the compact and relaxed chromatin structure of the promoter, respectively. Once in the active state (GENE1, Additional File 1: Figure S1), the gene is transcribed at a relatively constant rate; in the inactive state (GENE0), no transcription occurs. Transitions between the inactive and active states (i.e., gene activation and deactivation) are controlled by transcriptional activators and repressors specifically targeting the promoter. In addition to promoter transition, subsequent steps including transcription, translation, and mRNA and protein degradation were modeled for each of the three transcriptional repressors. Since these key steps contribute, to varying degrees, to the stochastic fluctuation of gene expression [38–44], their explicit inclusion adds variability to the switching behavior of the bistable circuit. In turn, the stochastic behavior of the bistable switch likely forms the basis for the heterogeneous differentiation response observed for a population of B cells stimulated with an antigen or B cell activator [22, 32, 34].
The negative mutual regulation among Bcl-6, Blimp-1, and Pax5 is modeled based on the modes of repression reported in the literature. Blimp-1 represses gene expression of both Bcl-6 and Pax5 [15–17]. As a transcriptional repressor, Blimp-1 suppresses target genes by recruiting co-repressors such as histone deacetylase, histone methyltranferase, and those belonging to the Groucho family [52–54]. Functioning as chromatin-modifying enzymes, these co-repressors alter the local chromatin structure to a compact (transcriptionally inactive) state. Based on this active mode of repression, the transcriptional repression of Bcl-6 and Pax5 by Blimp-1 was implemented by having Blimp-1 promote the deactivation step of these two genes. Pax5 in turn represses Blimp-1 gene expression directly , also by an active mechanism mediated through recruitment of co-repressors from the Groucho family [55, 56]. Therefore, repression of Blimp-1 by Pax5 was implemented by having Pax5 promote the deactivation step of Blimp-1 gene. Although the transcriptional repressor Bcl-6 may directly bind to target genes, it exerts its effect on Blimp-1 indirectly through AP-1. By binding and sequestering AP-1, Bcl-6 blocks its transcriptional activity, thus functioning as a passive repressor . Since AP-1 positively regulates Blimp-1 gene expression, repression of Blimp-1 by Bcl-6 was implemented by having Bcl-6 impinge upon the activation step of Blimp-1 gene, thus curbing the maximal induction of Blimp-1 by AP-1. Through these specific transcriptional regulations, a gene circuit is established in the form of coupled double-negative feedback loops among Bcl-6, Blimp-1, and Pax5 (Additional File 1: Figure S1).
Activation of the transcriptional program underlying B cell terminal differentiation occurs in a stimulus-dependent manner, involving various cytokines and cell surface receptors . In the case of LPS, binding to its cognate Toll-like receptor 4 (TLR4) initiates a sequence of intermediate intracellular signaling events, culminating in the activation of the AP-1 protein complex [34, 35]. For simplicity, the activation of AP-1 by LPS-bound TLR4 was modeled as a single phosphorylation event. Like many other membrane-residing receptors, TLR4 is usually downregulated after occupied by LPS, possibly through a desensitization mechanism that includes receptor internalization [57, 58]. Downregulation of TLR4 was implemented here by ascribing a higher rate constant to the turnover of the LPS-bound receptor compared to that of the free receptor. Inclusion of TLR4 downregulation enables the model to recapitulate the attenuation of AP-1 signaling in time following its initial activation, as observed in B cells stimulated with LPS and other cytokines [34, 35].
The suppression of AP-1 activity by TCDD in LPS-activated B cells was assumed to occur in an AhR-dependent manner. Although the precise mechanism for this process is unknown, a decrease in the AP-1 subunit c-jun was observed in the AP-1 DNA-binding complex in the presence of TCDD . For simplicity, AP-1 was treated as a single entity in our model with its synthesis rate negatively regulated by TCDD. In the absence of detailed information at the molecular level on the signaling pathways by which TCDD-AhR affects AP-1, the specific regulation of AP-1 by TCDD-AhR was described in the equation as a continuous function of the concentration of TCDD-AhR. Immunoglobulin M (IgM), which consists of several subunits, was also modeled as a single entity subject to negative control by both Pax5 and AhR. A first-order secretion rate was assumed for intracellular IgM, with the rate constant large enough that intracellular degradation of IgM is negligible.
Model implementation and modeling tools
Reaction details including ordinary differential equations, parameter values, and initial steady-state conditions are provided in Additional File 1: Tables S1 - S3. Unless otherwise indicated, the unit of abundance used for state variables in the model is number of molecules per cell. The deterministic version of the model was implemented in PathwayLab (InNetics Inc., Linköping, Sweden), while the stochastic version was implemented in the BioNetS program , based on Gillespie's stochastic simulation algorithm . Both versions of the model were exported into MatLab (The Mathworks, Inc., Natick, MA, USA) for analysis and simulation. The model in SBML format is provided in Additional File 2. Bifurcation diagrams were generated using the XPP-AUT program . The effective Hill coefficients (nH) of simulation-generated dose response curves were estimated by using the equation nH = ln81/ln(X90/X10), where X90 and X10 are the doses that produce 90% and 10% of the maximal response, respectively.
Bistability of the coupled double-negative feedback loops
By activating AP-1, LPS triggers the differentiation of B cells to plasma cells. Bifurcation analysis (Figure 2B) indicates that as the steady-state AP-1p (active form of AP-1) level increases (rightward arrows), Blimp-1 increases and Pax5 decreases initially by small amounts. However, once AP-1p reaches a threshold value of about 200 molecules, the B cell switches in a discrete fashion to a plasma cell state (vertical arrows). This abrupt transition underlies an all-or-none, switch-like response and signifies a true discontinuity that precludes the cell from settling at an intermediate state. The switch also exhibits hysteresis. Starting from the plasma cell state, as AP-1p is reduced (leftward arrows) to its basal level (~100), the system remains in the differentiated plasma cell state with high Blimp-1 and low Pax5/Bcl-6 levels. In the context of humoral immune response, this irreversibility of the switch ensures that the antibody-secreting plasma cell phenotype persists after the initial antigen stimulus recedes, thus serving as a maintenance mechanism for the acquired immunity.
Stochastic response of B cells to LPS stimulation
In a deterministic model of a bistable system, the occurrence of switching from one state to the other and the time when it occurs are uniquely determined by the level of the input stimulus . If the biochemical circuits are nearly identical across a population of B cells, the individual responses of these cells would be expected to be similar. However, experimental observations indicate that the responses of individual cells to a given activator are rather heterogeneous [22, 32, 34], even in an isogenic B cell population . Some cells differentiate into antibody-secreting plasma cells at early times, some do so at late times, and many cells remain undifferentiated in the time window of observation. Thus the number of plasma cells that appear after B cell activation is time-dependent. This heterogeneous response pattern is likely to be important in shaping dose response behaviors, which are quantitative measurements necessary for evaluating the health risk of immune-suppressive chemicals. Therefore a more explicit description of the heterogeneous response of individual B cells is needed than is provided by a deterministic model.
Effects of noise in Blimp-1 protein expression on the steepness and position of the LPS dose response curves.
% plasma Cells
Disruption of the bistable switch by TCDD
Discussion and Conclusions
Many cellular processes in living organisms, including sex determination, lineage specification, cell differentiation, proliferation, and apoptosis, are irreversible, all-or-none (binary) phenomena. It is increasingly recognized that such binary cellular processes are controlled by bistable biochemical circuits, which ensure the discreteness and irreversibility of these processes [62, 70]. Most cellular bistable systems are based on molecular circuits of mutual activation and/or mutual inhibition between genes and proteins . These molecular circuits often involve a number of proteins forming multiple feedback loops, as observed in systems for cell cycle control, oocyte maturation in Xenopus laevis, cell lineage specification and differentiation, etc [11, 72–75]. The coupling of multiple feedback loops is believed to provide redundancy as well as robustness to the bistable property of the entire circuit [73, 76]. In the B cell transcriptional network, double negative feedback loops between Bcl-6, Blimp-1, and Pax5 are coupled at the Blimp-1 node. The resulting bistability produces two mutually exclusive transcriptional profiles: (1) high Bcl-6/Pax5 and low Blimp-1, representing the B cell state; and (2) low Bcl-6/Pax5 and high Blimp-1, representing the plasma cell state (Figure 2A). This mutual exclusivity of stable gene expression patterns ensures definitive separation between two discrete cellular phenotypes and an all-or-none response in individual B cells to antigen stimulation. Further, once a B cell differentiates into a plasma cell, the plasma cell phenotype is retained even if the stimulating antigen is removed. This irreversibility is underpinned by hysteresis, another important biological property conferred by the bistable system (Figure 2B).
The switching from the B cell to plasma cell state is stimulated by specific antigens or polyclonal activators. In the case of LPS, the switching is mediated by alterations in concentration of active AP-1 protein (AP-1p) and characterized by a threshold concentration of AP-1p (Figure 2B). This in turn suggests a threshold for LPS, the initiating stimulus, and a switch-like dose response in a deterministic setting. In reality, the bistable gene circuit in the B cell has to operate in an inherently stochastic environment within the nucleus, which is likely to produce significant cell-to-cell variability. Our experimental data shows that individual B cells differentiate into plasma cells in a rather heterogeneous manner, with the percentage of plasma cells formed appearing to be a graded function of the LPS dose, devoid of the sharp transitions expected for an all-or-none bistable switch (Figure 6A). By considering the stochasticity in gene expression, our simulations recapitulate these observations. Thus whether a particular B cell will respond or not within a given time window of LPS stimulation, as well as the timing of the response, are both chance events resulting from intrinsically stochastic gene expression.
Due to the low expression level of Blimp-1 in B cells , its abundance is likely to show considerable moment-to-moment and cell-to-cell variability. In our implementation of the B-cell differentiation network, Blimp-1 fluctuates in a nearly pulsatile manner (Figure 3), which is consistent with the phenomenon of pulsatile mRNA production and bursting of protein translation observed for genes with low expression [77–80]. In the phase space of the bistable system, mature B cells would reside on one side of an imaginary boundary separating the two basins of attraction for the B cell and plasma cell states. Even in the absence of LPS, an occasional pulse in Blimp-1 expression may be large enough to send the system across the boundary to the plasma cell state. This might explain the spontaneous appearance of a negligibly small fraction of plasma cells observed in a population of B cells in vitro in the absence of any antigen [22, 23, 34, 81]. Exposure to LPS, which activates the AP-1 protein, leads to increased Blimp-1 gene transcription. Due to the stochastic nature of Blimp-1 gene expression, the LPS-induced increase in Blimp-1 abundance takes the form of more frequent and larger Blimp-1 pulses (Additional File 1: Figure S7). These pulses increase the probability of the system crossing the fate-separating boundary and then being attracted to the plasma cell state eventually. Our analysis suggests that the cell-to-cell variability in Blimp-1 pulses at a given moment explains the heterogeneous switching behavior of individual B cells. Previous computational studies have shown that stochastic fluctuations could obscure the threshold of the switching behavior of a bistable system, making the dose response less switch-like [82, 83]. In our implementation of the B cell differentiation network, sufficiently large stochastic fluctuations in Blimp-1 expression result in substantially graded response for percentage plasma cell formation with an estimated Hill coefficient close to 1. This number, a measure of the steepness of the dose response curve, is inversely correlated with the level of noise in Blimp-1 protein expression (Figure 7 and Table 1).
In summary, the bistable gene circuit operating in a stochastic environment in B cells confers two essential properties to the humoral immune response. First, bistability ensures that distinct, mutually exclusive phenotypes are associated with the B cell and plasma cell, and that the switching from the B cell to plasma cell phenotype is irreversible so as to maintain the acquired immunity for a period of time following antigen encounter. Second, stochastic fluctuations in protein expression provide the necessary variability for the differentiation response to becomes probabilistic. This allows the number of plasma cells formed and the total amount of antibody produced to scale in a graded manner with the antigen dose. Numerous studies have shown that noise in protein expression can be exploited by cells to generate necessary non-genetic variability in cellular phenotype and fate [12, 45–47, 84–86]. For example, intrinsic noise in ComK protein expression in the soil bacterium Bacillus subtilis allows a small fraction of cells to reside in the competent state capable of DNA uptake rather than in a vegetative state. This strategy increases fitness of the species by increasing phenotypic diversity among a population of genetically identical bacteria [12, 87]. A recent study by Spencer et al. demonstrated that protein expression noise may be responsible for the variability in apoptotic response observed in clonal populations of mammalian cells . It is thus likely that noise in gene expression is utilized by B cells to launch a humoral immune response of appropriate magnitude (as measured by the extent of plasma cell formation and aggregated IgM secretion) in handling the amount of pathogen in the body. This proposed effect of variability at the molecular level on the overall dose response curves is similar to the hypothesis on chemical carcinogenesis at the human population level proposed by Lutz, which states that even if each human individual had a specific response threshold for a carcinogen, variability among individuals would result in a continuous dose response curve for a human population .
The molecular basis of the immunosuppressive effect of the environmental contaminant TCDD and similar compounds acting through AhR remains incompletely understood at the molecular level. A primary goal in developing cell-based quantitative network simulations of toxic response is to evaluate the shape of the dose response curve over a broad range of exposures. To this end, it is necessary to acquire mechanistic understanding of how dioxin-like compounds interact with the gene transcriptional network underlying the B cell terminal differentiation program. As we have tried to demonstrate in the current work, computational modeling approaches can be helpful in attaining this goal. Through activation of the AhR signaling pathway, TCDD, a potent dioxin compound, suppresses AP-1 signaling, a key mediator of B cell differentiation [35, 36]. This attenuation of antigen-stimulated AP-1 activation by TCDD (Additional File 1: Figure S6) makes it more difficult for a B cell to switch to the plasma cell state. In a stochastic gene expression context, this inhibitory effect of TCDD is manifested as a reduction in the probability of B cell differentiation. With fewer antibody-secreting plasma cells formed, the humoral immunity is compromised. Importantly, stochasticity in gene expression of transcription factors transforms the binary, all-or-none response occurring in individual B cells into a much more graded response to TCDD for a population of B cells (Figure 8). Our computational model, which incorporates as default a continuous description of TCDD affecting AP-1 and simulates in vitro experimental scenarios, suggests that the graded nature of the suppressive effect on B cell differentiation may extend well into the low-dose region, where no abrupt transitions were observed (Additional File 1: Figure S5).
Differentiation of mature B cells into plasma cells is a terminal, physiologically irreversible process. Some of the newly differentiated plasma cells migrate to the bone marrow, where, aided by survival signals from stromal cells, they can survive for several months [89–91]. Independent of memory B cells, these long-lived plasma cells contribute to acquired immunity against pathogens by continuing to secrete antibody molecules for an extended period of time. While the effect on B cell differentiation has been a focus of research concerning immunotoxicity of TCDD and related compounds, its possible effect on the fate of terminally differentiated plasma cells has not received much attention. In its present form, our B cell response network suggests that TCDD may alter the phase space landscape of the transcription program, bringing the plasma cell state closer to the boundary separating it from the B cell state (Figure 11A). This would make it easier for stochastic fluctuations to switch plasma cells back to the B cell state. This behavior occurs in the stochastic implementation but not in the deterministic mode with an identical parameter set. Stochastic simulations suggest that TCDD destabilizes plasma cells in a dose-dependent manner, possibly allowing these cells to dedifferentiate back to a B cell phenotype (Figure 11B). While the predicted decline in the number of plasma cells due to phenotype reversal is a slow process, the impairment to the acquired humoral immunity could be tangible, given that long-lived plasma cells may survive in the bone marrow for up to several months [89–91].
Although cell differentiation is traditionally regarded as a physiologically irreversible process, gene manipulation in terminally differentiated cells has been shown to successfully reprogram these cells to progenitor or even stem cell states [92–95]. Among immune cells, the B cell lineage itself has considerable plasticity [96, 97]. B cells can be dedifferentiated by genetic manipulation to precursor cells, and thereafter diverted through intermediate states to fully differentiated T cells or macrophages [98, 99]. Transiently expressing ectopic Bcl-6 and associated co-repressor MTA3 in plasma cell lines reversed the phenotype to that of B cells . This finding is consistent with our model of the underlying bistable gene circuit, where TCDD first represses AP-1 and Blimp-1, leading to upregulation of Bcl-6 and Pax5, and consequent destabilization of the plasma cell state. While this prediction requires further study, it could have important implications for the immunotoxicity of TCDD. If confirmed, it would imply that besides suppressing initiation of the humoral immune response by inhibiting plasma cell formation, TCDD and similar compounds may disrupt the maintenance of the humoral response through destabilization of long-lived plasma cells.
Although the stochastic model presented here reproduces some experimental observations, the entire transcriptional network of B cell differentiation is potentially far more complex. Besides Bcl-6, Blimp-1, and Pax5, additional transcription factors such as Bach2, IRF-4, Mad1, and MTA3 are also involved in regulation of B-to-plasma cell differentiation [26, 33, 101–103]. Additional feedback loops may also exist, for example between Blimp-1 and IRF-4 . The molecular pathways mediating the toxicity of TCDD are also likely to be more extensive than the impairment of AP-1 signaling. For instance, the role of the AhR repressor protein in TCDD signaling may need to be considered . An important purpose of risk assessment for TCDD and other dioxin-like compounds is to establish specific "safe" values of exposure in the low-dose region, below which adverse biological effects are negligibly small. However, low-dose effects are generally more difficult to measure precisely and economically, as the variability associated with measured endpoints is usually large, obscuring the change in curvature of the low-dose region. Estimation of low-dose effects is therefore frequently made by extrapolation from high-dose data or computer simulations. In the present study, we show that a mechanistic, systems-level computational model of the B cell transcriptional network incorporating stochastic gene expression could generate dose response curves for a broad range of doses in agreement with experimental measurements. However, its value in accurately predicting low-dose effects for both LPS and TCDD is currently limited. A more confident prediction would likely require greater structural and kinetic details of pertinent signaling pathways leading from exposure to LPS and TCDD up to the bistable circuit, and perhaps a more complete description of the bistable circuit itself. Finally, for in vivo toxicity prediction, the cellular model has to be linked to dosimetry models that calculate the concentrations of dioxin-like compounds in immune tissues for environmental exposures.
In conclusion, we demonstrate that a bistable gene regulatory network comprising three genes - Bcl-6, Blimp-1, and Pax5 - exhibits behavior consistent with the terminal differentiation of B lymphocytes to antibody-secreting plasma cells. In a stochastic gene expression environment, the response to both antigen and TCDD at the cell population level appears to be substantially graded even though activation of individual cell is a binary, all-or-none phenomenon.
We would like to thank the Superfund Research Program (P42ES04911) from the National Institute of Environmental Health Sciences for supporting this work.
- Shapiro-Shelef M, Calame K: Regulation of plasma-cell development. Nat Rev Immunol. 2005, 5: 230-242. 10.1038/nri1572PubMedGoogle Scholar
- Calame KL: Plasma cells: finding new light at the end of B cell development. Nat Immunol. 2001, 2: 1103-1108. 10.1038/ni1201-1103PubMedGoogle Scholar
- Peden-Adams MM, Keller JM, Eudaly JG, Berger J, Gilkeson GS, Keil DE: Suppression of humoral immunity in mice following exposure to perfluorooctane sulfonate. Toxicol Sci. 2008, 104: 144-154. 10.1093/toxsci/kfn059PubMedGoogle Scholar
- Salazar KD, de la Rosa P, Barnett JB, Schafer R: The polysaccharide antibody response after Streptococcus pneumoniae vaccination is differentially enhanced or suppressed by 3, 4-dichloropropionanilide and 2, 4-dichlorophenoxyacetic acid. Toxicol Sci. 2005, 87: 123-133. 10.1093/toxsci/kfi244PubMedGoogle Scholar
- Dooley RK, Holsapple MP: Elucidation of cellular targets responsible for tetrachlorodibenzo-p-dioxin (TCDD)-induced suppression of antibody responses: I. The role of the B lymphocyte. Immunopharmacology. 1988, 16: 167-180. 10.1016/0162-3109(88)90005-7PubMedGoogle Scholar
- Tucker AN, Vore SJ, Luster MI: Suppression of B cell differentiation by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin. Mol Pharmacol. 1986, 29: 372-377.PubMedGoogle Scholar
- Sulentic CE, Holsapple MP, Kaminski NE: Aryl hydrocarbon receptor-dependent suppression by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin of IgM secretion in activated B cells. Mol Pharmacol. 1998, 53: 623-629.PubMedGoogle Scholar
- Kerkvliet NI: Recent advances in understanding the mechanisms of TCDD immunotoxicity. Int Immunopharmacol. 2002, 2: 277-291. 10.1016/S1567-5769(01)00179-5PubMedGoogle Scholar
- Poland A, Knutson JC: 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu Rev Pharmacol Toxicol. 1982, 22: 517-554. 10.1146/annurev.pa.22.040182.002505PubMedGoogle Scholar
- Huang S, Guo YP, May G, Enver T: Bifurcation dynamics in lineage-commitment in bipotent progenitor cells. Dev Biol. 2007, 305: 695-713. 10.1016/j.ydbio.2007.02.036PubMedGoogle Scholar
- Chickarmane V, Troein C, Nuber UA, Sauro HM, Peterson C: Transcriptional dynamics of the embryonic stem cell switch. PLoS Comput Biol. 2006, 2: e123- 10.1371/journal.pcbi.0020123PubMed CentralPubMedGoogle Scholar
- Maamar H, Raj A, Dubnau D: Noise in gene expression determines cell fate in Bacillus subtilis. Science. 2007, 317: 526-529. 10.1126/science.1140818PubMedGoogle Scholar
- Rosen ED, MacDougald OA: Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol. 2006, 7: 885-896. 10.1038/nrm2066PubMedGoogle Scholar
- Calame K: Activation-dependent induction of Blimp-1. Curr Opin Immunol. 2008, 20: 259-264. 10.1016/j.coi.2008.04.010PubMedGoogle Scholar
- Lin KI, Angelin-Duclos C, Kuo TC, Calame K: Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol Cell Biol. 2002, 22: 4771-4780. 10.1128/MCB.22.13.4771-4780.2002PubMed CentralPubMedGoogle Scholar
- Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A, Giltnane JM, Yang L, Zhao H, Calame K, Staudt LM: Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity. 2002, 17: 51-62. 10.1016/S1074-7613(02)00335-7PubMedGoogle Scholar
- Sciammas R, Davis MM: Modular nature of Blimp-1 in the regulation of gene expression during B cell maturation. J Immunol. 2004, 172: 5427-5440.PubMedGoogle Scholar
- Vasanwala FH, Kusam S, Toney LM, Dent AL: Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J Immunol. 2002, 169: 1922-1929.PubMedGoogle Scholar
- Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame KL: Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol. 2004, 173: 1158-1165.PubMedGoogle Scholar
- Mora-Lopez F, Reales E, Brieva JA, Campos-Caro A: Human BSAP and BLIMP1 conform an autoregulatory feedback loop. Blood. 2007, 110: 3150-3157. 10.1182/blood-2007-05-092262PubMedGoogle Scholar
- Bhattacharya S, Conolly RB, Kaminski NE, Thomas RS, Andersen ME, Zhang Q: A Bistable Switch Underlying B Cell Differentiation and Its Disruption by the Environmental Contaminant 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin. Toxicol Sci. 2010, doi: 10.1093/toxsci/kfq1035,Google Scholar
- Soro PG, Morales AP, Martinez MJ, Morales AS, Copin SG, Marcos MA, Gaspar ML: Differential involvement of the transcription factor Blimp-1 in T cell-independent and -dependent B cell differentiation to plasma cells. J Immunol. 1999, 163: 611-617.PubMedGoogle Scholar
- Kallies A, Hasbold J, Tarlinton DM, Dietrich W, Corcoran LM, Hodgkin PD, Nutt SL: Plasma cell ontogeny defined by quantitative changes in blimp-1 expression. J Exp Med. 2004, 200: 967-977. 10.1084/jem.20040973PubMed CentralPubMedGoogle Scholar
- Fairfax KA, Corcoran LM, Pridans C, Huntington ND, Kallies A, Nutt SL, Tarlinton DM: Different kinetics of blimp-1 induction in B cell subsets revealed by reporter gene. J Immunol. 2007, 178: 4104-4111.PubMedGoogle Scholar
- Kallies A, Hasbold J, Fairfax K, Pridans C, Emslie D, McKenzie BS, Lew AM, Corcoran LM, Hodgkin PD, Tarlinton DM, Nutt SL: Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. Immunity. 2007, 26: 555-566. 10.1016/j.immuni.2007.04.007PubMedGoogle Scholar
- Klein U, Casola S, Cattoretti G, Shen Q, Lia M, Mo T, Ludwig T, Rajewsky K, Dalla-Favera R: Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol. 2006, 7: 773-782. 10.1038/ni1357PubMedGoogle Scholar
- Johnson K, Shapiro-Shelef M, Tunyaplin C, Calame K: Regulatory events in early and late B-cell differentiation. Mol Immunol. 2005, 42: 749-761. 10.1016/j.molimm.2004.06.039PubMedGoogle Scholar
- Cobaleda C, Schebesta A, Delogu A, Busslinger M: Pax5: the guardian of B cell identity and function. Nat Immunol. 2007, 8: 463-470. 10.1038/ni1454PubMedGoogle Scholar
- Delogu A, Schebesta A, Sun Q, Aschenbrenner K, Perlot T, Busslinger M: Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity. 2006, 24: 269-281. 10.1016/j.immuni.2006.01.012PubMedGoogle Scholar
- Diehl SA, Schmidlin H, Nagasawa M, van Haren SD, Kwakkenbos MJ, Yasuda E, Beaumont T, Scheeren FA, Spits H: STAT3-mediated up-regulation of BLIMP1 Is coordinated with BCL6 down-regulation to control human plasma cell differentiation. J Immunol. 2008, 180: 4805-4815.PubMed CentralPubMedGoogle Scholar
- Niu H, Ye BH, Dalla-Favera R: Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev. 1998, 12: 1953-1961. 10.1101/gad.12.13.1953PubMed CentralPubMedGoogle Scholar
- Rui L, Healy JI, Blasioli J, Goodnow CC: ERK signaling is a molecular switch integrating opposing inputs from B cell receptor and T cell cytokines to control TLR4-driven plasma cell differentiation. J Immunol. 2006, 177: 5337-5346.PubMedGoogle Scholar
- Walker SR, Nelson EA, Frank DA: STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene. 2007, 26: 224-233. 10.1038/sj.onc.1209775PubMedGoogle Scholar
- Ohkubo Y, Arima M, Arguni E, Okada S, Yamashita K, Asari S, Obata S, Sakamoto A, Hatano M, J OW, et al.: A role for c-fos/activator protein 1 in B lymphocyte terminal differentiation. J Immunol. 2005, 174: 7703-7710.PubMedGoogle Scholar
- Suh J, Jeon YJ, Kim HM, Kang JS, Kaminski NE, Yang KH: Aryl hydrocarbon receptor-dependent inhibition of AP-1 activity by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in activated B cells. Toxicol Appl Pharmacol. 2002, 181: 116-123. 10.1006/taap.2002.9403PubMedGoogle Scholar
- Schneider D, Manzan MA, Yoo BS, Crawford RB, Kaminski N: Involvement of Blimp-1 and AP-1 dysregulation in the 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin-mediated suppression of the IgM response by B cells. Toxicol Sci. 2009, 108: 377-388. 10.1093/toxsci/kfp028PubMed CentralPubMedGoogle Scholar
- Sulentic CE, Zhang W, Na YJ, Kaminski NE: 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin, an exogenous modulator of the 3'alpha immunoglobulin heavy chain enhancer in the CH12.LX mouse cell line. J Pharmacol Exp Ther. 2004, 309: 71-78. 10.1124/jpet.103.059493PubMedGoogle Scholar
- Kaern M, Elston TC, Blake WJ, Collins JJ: Stochasticity in gene expression: from theories to phenotypes. Nat Rev Genet. 2005, 6: 451-464. 10.1038/nrg1615PubMedGoogle Scholar
- Thattai M, van Oudenaarden A: Intrinsic noise in gene regulatory networks. Proc Natl Acad Sci USA. 2001, 98: 8614-8619. 10.1073/pnas.151588598PubMed CentralPubMedGoogle Scholar
- Elowitz MB, Levine AJ, Siggia ED, Swain PS: Stochastic gene expression in a single cell. Science. 2002, 297: 1183-1186. 10.1126/science.1070919PubMedGoogle Scholar
- Ozbudak EM, Thattai M, Kurtser I, Grossman AD, van Oudenaarden A: Regulation of noise in the expression of a single gene. Nat Genet. 2002, 31: 69-73. 10.1038/ng869PubMedGoogle Scholar
- Swain PS, Elowitz MB, Siggia ED: Intrinsic and extrinsic contributions to stochasticity in gene expression. Proc Natl Acad Sci USA. 2002, 99: 12795-12800. 10.1073/pnas.162041399PubMed CentralPubMedGoogle Scholar
- Blake WJ, M KA, Cantor CR, Collins JJ: Noise in eukaryotic gene expression. Nature. 2003, 422: 633-637. 10.1038/nature01546PubMedGoogle Scholar
- Raser JM, O'Shea EK: Control of stochasticity in eukaryotic gene expression. Science. 2004, 304: 1811-1814. 10.1126/science.1098641PubMed CentralPubMedGoogle Scholar
- Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK: Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature. 2009, 459: 428-432. 10.1038/nature08012PubMed CentralPubMedGoogle Scholar
- Kar S, Baumann WT, Paul MR, Tyson JJ: Exploring the roles of noise in the eukaryotic cell cycle. Proc Natl Acad Sci USA. 2009, 106: 6471-6476. 10.1073/pnas.0810034106PubMed CentralPubMedGoogle Scholar
- Wernet MF, Mazzoni EO, Celik A, Duncan DM, Duncan I, Desplan C: Stochastic spineless expression creates the retinal mosaic for colour vision. Nature. 2006, 440: 174-180. 10.1038/nature04615PubMedGoogle Scholar
- Lu H, Kaplan BL, Ngaotepprutaram T, Kaminski NE: Suppression of T cell costimulator ICOS by Delta9-tetrahydrocannabinol. J Leukoc Biol. 2009, 85: 322-329. 10.1189/jlb.0608390PubMed CentralPubMedGoogle Scholar
- Springs AE, Karmaus PW, Crawford RB, Kaplan BL, Kaminski NE: Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol. J Leukoc Biol. 2008, 84: 1574-1584. 10.1189/jlb.0508282PubMed CentralPubMedGoogle Scholar
- Fiering S, Whitelaw E, Martin DI: To be or not to be active: the stochastic nature of enhancer action. Bioessays. 2000, 22: 381-387. 10.1002/(SICI)1521-1878(200004)22:4<381::AID-BIES8>3.0.CO;2-EPubMedGoogle Scholar
- Zhang Q, Andersen ME, Conolly RB: Binary Gene Induction and Protein Expression in Individual Cells. Theor Biol Med Model. 2006, 3: 18- 10.1186/1742-4682-3-18PubMed CentralPubMedGoogle Scholar
- Yu J, Angelin-Duclos C, Greenwood J, Liao J, Calame K: Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. Mol Cell Biol. 2000, 20: 2592-2603. 10.1128/MCB.20.7.2592-2603.2000PubMed CentralPubMedGoogle Scholar
- Gyory I, Wu J, Fejer G, Seto E, Wright KL: PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat Immunol. 2004, 5: 299-308. 10.1038/ni1046PubMedGoogle Scholar
- Ren B, Chee KJ, Kim TH, Maniatis T: PRDI-BF1/Blimp-1 repression is mediated by corepressors of the Groucho family of proteins. Genes Dev. 1999, 13: 125-137. 10.1101/gad.13.1.125PubMed CentralPubMedGoogle Scholar
- Milili M, Gauthier L, Veran J, Mattei MG, Schiff C: A new Groucho TLE4 protein may regulate the repressive activity of Pax5 in human B lymphocytes. Immunology. 2002, 106: 447-455. 10.1046/j.1365-2567.2002.01456.xPubMed CentralPubMedGoogle Scholar
- Eberhard D, Jimenez G, Heavey B, Busslinger M: Transcriptional repression by Pax5 (BSAP) through interaction with corepressors of the Groucho family. Embo J. 2000, 19: 2292-2303. 10.1093/emboj/19.10.2292PubMed CentralPubMedGoogle Scholar
- Husebye H, Halaas O, Stenmark H, Tunheim G, Sandanger O, Bogen B, Brech A, Latz E, Espevik T: Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity. Embo J. 2006, 25: 683-692. 10.1038/sj.emboj.7600991PubMed CentralPubMedGoogle Scholar
- Kitchens RL, Wang P, Munford RS: Bacterial lipopolysaccharide can enter monocytes via two CD14-dependent pathways. J Immunol. 1998, 161: 5534-5545.PubMedGoogle Scholar
- Adalsteinsson D, McMillen D, Elston TC: Biochemical Network Stochastic Simulator (BioNetS): software for stochastic modeling of biochemical networks. BMC Bioinformatics. 2004, 5: 24- 10.1186/1471-2105-5-24PubMed CentralPubMedGoogle Scholar
- Gillespie DT: Exact stochastic simulation of coupled chemical reactions. Journal of Physical Chemistry. 1977, 81: 2340-2361. 10.1021/j100540a008.Google Scholar
- Ermentrout B: Simulating, Analyzing, and Animating Dynamical Systems: A Guide to XPPAUT for Researchers and Students. 2002, Philadelphia, USA: SIAM, 1,Google Scholar
- Ferrell JE, Xiong W: Bistability in cell signaling: How to make continuous processes discontinuous, and reversible processes irreversible. Chaos. 2001, 11: 227-236. 10.1063/1.1349894PubMedGoogle Scholar
- Angeli D, Ferrell JE, Sontag ED: Detection of multistability, bifurcations, and hysteresis in a large class of biological positive-feedback systems. Proc Natl Acad Sci USA. 2004, 101: 1822-1827. 10.1073/pnas.0308265100PubMed CentralPubMedGoogle Scholar
- Strogatz SH: Nonliear dynamics and chaos: with applications to physics, biology, chemistry, and engineering. 1994, Cambridge: Perseus Books Group, 1,Google Scholar
- Swain SL, Dutton RW, McKenzie D, Helstrom H, English M: Role of antigen in the B cell response. Specific antigen and the lymphokine IL-5 synergize to drive B cell lymphoma proliferation and differentiation to Ig secretion. J Immunol. 1988, 140: 4224-4230.PubMedGoogle Scholar
- Turner CA, Mack DH, Davis MM: Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell. 1994, 77: 297-306. 10.1016/0092-8674(94)90321-2PubMedGoogle Scholar
- North CM, Kim BS, Snyder N, Crawford RB, Holsapple MP, Kaminski NE: TCDD-Mediated Suppression of the in vitro Anti-Sheep Erythrocyte IgM Antibody Forming Cell Response is Reversed by Interferon Gamma. Toxicol Sci. 2009, 107: 85-92. 10.1093/toxsci/kfn223PubMed CentralPubMedGoogle Scholar
- Schneider D, Manzan MA, Crawford RB, Chen W, Kaminski NE: 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin-mediated impairment of B cell differentiation involves dysregulation of paired box 5 (Pax5) isoform, Pax5a. J Pharmacol Exp Ther. 2008, 326: 463-474. 10.1124/jpet.108.139857PubMed CentralPubMedGoogle Scholar
- Crawford RB, Sulentic CE, Yoo BS, Kaminski NE: 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the regulation and posttranslational modification of p27kip1 in lipopolysaccharide-activated B cells. Toxicol Sci. 2003, 75: 333-342. 10.1093/toxsci/kfg199PubMedGoogle Scholar
- Pomerening JR: Uncovering mechanisms of bistability in biological systems. Curr Opin Biotechnol. 2008, 19: 381-388. 10.1016/j.copbio.2008.06.009PubMedGoogle Scholar
- Ferrell JE: Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability. Curr Opin Cell Biol. 2002, 14: 140-148. 10.1016/S0955-0674(02)00314-9PubMedGoogle Scholar
- Xiong W, Ferrell JE: A positive-feedback-based bistable 'memory module' that governs a cell fate decision. Nature. 2003, 426: 460-465. 10.1038/nature02089PubMedGoogle Scholar
- Ferrell JE: Feedback regulation of opposing enzymes generates robust, all-or-none bistable responses. Curr Biol. 2008, 18: R244-245. 10.1016/j.cub.2008.02.035PubMed CentralPubMedGoogle Scholar
- Palani S, Sarkar CA: Positive receptor feedback during lineage commitment can generate ultrasensitivity to ligand and confer robustness to a bistable switch. Biophys J. 2008, 95: 1575-1589. 10.1529/biophysj.107.120600PubMed CentralPubMedGoogle Scholar
- Sveiczer A, Tyson JJ, Novak B: Modelling the fission yeast cell cycle. Brief Funct Genomic Proteomic. 2004, 2: 298-307. 10.1093/bfgp/2.4.298PubMedGoogle Scholar
- Kim JR, Yoon Y, Cho KH: Coupled feedback loops form dynamic motifs of cellular networks. Biophys J. 2008, 94: 359-365. 10.1529/biophysj.107.105106PubMed CentralPubMedGoogle Scholar
- Yu J, Xiao J, Ren X, Lao K, Xie XS: Probing gene expression in live cells, one protein molecule at a time. Science. 2006, 311: 1600-1603. 10.1126/science.1119623PubMedGoogle Scholar
- Cai L, Friedman N, Xie XS: Stochastic protein expression in individual cells at the single molecule level. Nature. 2006, 440: 358-362. 10.1038/nature04599PubMedGoogle Scholar
- Raj A, Peskin CS, Tranchina D, Vargas DY, Tyagi S: Stochastic mRNA synthesis in mammalian cells. PLoS Biol. 2006, 4: e309- 10.1371/journal.pbio.0040309PubMed CentralPubMedGoogle Scholar
- Golding I, Paulsson J, Zawilski SM, Cox EC: Real-time kinetics of gene activity in individual bacteria. Cell. 2005, 123: 1025-1036. 10.1016/j.cell.2005.09.031PubMedGoogle Scholar
- Tumang JR, Frances R, Yeo SG, Rothstein TL: Spontaneously Ig-secreting B-1 cells violate the accepted paradigm for expression of differentiation-associated transcription factors. J Immunol. 2005, 174: 3173-3177.PubMedGoogle Scholar
- Lai K, Robertson MJ, Schaffer DV: The sonic hedgehog signaling system as a bistable genetic switch. Biophys J. 2004, 86: 2748-2757. 10.1016/S0006-3495(04)74328-3PubMed CentralPubMedGoogle Scholar
- Bhattacharya S, Zhang Q, Andersen ME: The Role of Core Biological Motifs in Dose-Response Modeling: An Example with Switch-Like Circuits. Systems Biology in Drug Discovery and Development. Edited by: Young D, Michelson S. 2009, Hoboken, New Jersey: John Wiley & Sons, ,Google Scholar
- Losick R, Desplan C: Stochasticity and cell fate. Science. 2008, 320: 65-68. 10.1126/science.1147888PubMed CentralPubMedGoogle Scholar
- Chang HH, Hemberg M, Barahona M, Ingber DE, Huang S: Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature. 2008, 453: 544-547. 10.1038/nature06965PubMedGoogle Scholar
- Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV: Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell. 2005, 122: 169-182. 10.1016/j.cell.2005.06.006PubMedGoogle Scholar
- Suel GM, Kulkarni RP, Dworkin J, Garcia-Ojalvo J, Elowitz MB: Tunability and noise dependence in differentiation dynamics. Science. 2007, 315: 1716-1719. 10.1126/science.1137455PubMedGoogle Scholar
- Lutz WK: A true threshold dose in chemical carcinogenesis cannot be defined for a population, irrespective of the mode of action. Hum Exp Toxicol. 2000, 19: 566-568. discussion 571-562, 10.1191/096032700701546488PubMedGoogle Scholar
- Manz RA, Thiel A, Radbruch A: Lifetime of plasma cells in the bone marrow. Nature. 1997, 388: 133-134. 10.1038/40540PubMedGoogle Scholar
- Ahuja A, Anderson SM, Khalil A, Shlomchik MJ: Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci USA. 2008, 105: 4802-4807. 10.1073/pnas.0800555105PubMed CentralPubMedGoogle Scholar
- Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, Hiepe F: Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol. 2006, 6: 741-750. 10.1038/nri1886PubMedGoogle Scholar
- Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007, 131: 861-872. 10.1016/j.cell.2007.11.019PubMedGoogle Scholar
- Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, et al.: Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007, 318: 1917-1920. 10.1126/science.1151526PubMedGoogle Scholar
- Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ: Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008, 451: 141-146. 10.1038/nature06534PubMedGoogle Scholar
- Lowry WE, Richter L, Yachechko R, Pyle AD, Tchieu J, Sridharan R, Clark AT, Plath K: Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci USA. 2008, 105: 2883-2888. 10.1073/pnas.0711983105PubMed CentralPubMedGoogle Scholar
- Nutt SL: B-cell identity--commitment is not forever. N Engl J Med. 2008, 358: 82-83. 10.1056/NEJMcibr0707112PubMedGoogle Scholar
- Welner RS, Pelayo R, Kincade PW: Evolving views on the genealogy of B cells. Nat Rev Immunol. 2008, 8: 95-106. 10.1038/nri2234PubMedGoogle Scholar
- Xie H, Ye M, Feng R, Graf T: Stepwise reprogramming of B cells into macrophages. Cell. 2004, 117: 663-676. 10.1016/S0092-8674(04)00419-2PubMedGoogle Scholar
- Cobaleda C, Jochum W, Busslinger M: Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature. 2007, 449: 473-477. 10.1038/nature06159PubMedGoogle Scholar
- Fujita N, Jaye DL, Geigerman C, Akyildiz A, Mooney MR, Boss JM, Wade PA: MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell. 2004, 119: 75-86. 10.1016/j.cell.2004.09.014PubMedGoogle Scholar
- Lee SC, Bottaro A, Chen L, Insel RA: Mad1 is a transcriptional repressor of Bcl-6. Mol Immunol. 2006, 43: 1965-1971. 10.1016/j.molimm.2005.11.017PubMedGoogle Scholar
- Ochiai K, Katoh Y, Ikura T, Hoshikawa Y, Noda T, Karasuyama H, Tashiro S, Muto A, Igarashi K: Plasmacytic transcription factor Blimp-1 is repressed by Bach2 in B cells. J Biol Chem. 2006, 281: 38226-38223. 10.1074/jbc.M607592200PubMedGoogle Scholar
- Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H: Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity. 2006, 25: 225-236. 10.1016/j.immuni.2006.07.009PubMedGoogle Scholar
- Hahn ME, Allan LL, Sherr DH: Regulation of constitutive and inducible AHR signaling: complex interactions involving the AHR repressor. Biochem Pharmacol. 2009, 77: 485-497. 10.1016/j.bcp.2008.09.016PubMed CentralPubMedGoogle Scholar